Initial work supported the proposed oncogenic function of PVT1 in a murine model of breast cancer where genetically engineered Myc-Pvt1 co-amplification was observed to be more tumorigenic than Myc amplification alone [71]. The gene discussed is MYC; the disease is breast carcinoma.